Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Trial to Evaluate CA-4948 both as a Monotherapy and in Combination with Ibrutinib in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma or Other Hematologic Malignancies

Next Previous
Trial Profile

A Phase 1/2 Trial to Evaluate CA-4948 both as a Monotherapy and in Combination with Ibrutinib in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma or Other Hematologic Malignancies

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Emavusertib (Primary) ; Ibrutinib (Primary)
  • Indications CNS cancer; Diffuse large B cell lymphoma; Haematological malignancies; Lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Curis

Most Recent Events

  • 05 May 2022 According to a Curis media release, In the first half of 2022, the company plans to present new data for approximately 12 patients who have received treatment with the combination of emavusertib and ibrutinib at the upcoming American Society of Clinical Oncology and European Hematology Association
  • 09 Nov 2021 According to a Curis media release, company expects initial data at a medical meeting in the 1H 2022.
  • 03 Aug 2021 According to a Curis media release, the company expect to report initial data at a medical meeting in the 2H 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top